A new trading day began on Tuesday, with Amicus Therapeutics Inc (NASDAQ: FOLD) stock price up 1.54% from the previous day of trading, before settling in for the closing price of $9.72. FOLD’s price has ranged from $9.02 to $14.57 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 37.81%. Meanwhile, its annual earnings per share averaged 60.93%. With a float of $291.20 million, this company’s outstanding shares have now reached $293.59 million.
Let’s determine the extent of company efficiency that accounts for 517 employees. In terms of profitability, gross margin is 88.67%, operating margin of 2.28%, and the pretax margin is -13.85%.
Amicus Therapeutics Inc (FOLD) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Amicus Therapeutics Inc is 2.55%, while institutional ownership is 102.66%. The most recent insider transaction that took place on Nov 06 ’24, was worth 98,800. In this transaction President and CEO of this company sold 7,901 shares at a rate of $12.50, taking the stock ownership to the 886,654 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Director proposed sale 7,901 for $11.74, making the entire transaction worth $92,758.
Amicus Therapeutics Inc (FOLD) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 60.93% per share during the next fiscal year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Here are Amicus Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Looking closely at Amicus Therapeutics Inc (NASDAQ: FOLD), its last 5-days average volume was 1.92 million, which is a drop from its year-to-date volume of 2.71 million. As of the previous 9 days, the stock’s Stochastic %D was 31.39%. Additionally, its Average True Range was 0.40.
During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 15.63%, which indicates a significant decrease from 25.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.11% in the past 14 days, which was lower than the 40.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.77, while its 200-day Moving Average is $10.93. However, in the short run, Amicus Therapeutics Inc’s stock first resistance to watch stands at $9.98. Second resistance stands at $10.08. The third major resistance level sits at $10.24. If the price goes on to break the first support level at $9.72, it is likely to go to the next support level at $9.56. Should the price break the second support level, the third support level stands at $9.46.
Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats
With a market capitalization of 2.95 billion, the company has a total of 298,806K Shares Outstanding. Currently, annual sales are 399,360 K while annual income is -151,580 K. The company’s previous quarter sales were 141,520 K while its latest quarter income was -6,730 K.
